(SOURCE: UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE) – Approximately 500 million people around the world are infected with the genital herpes virus known as herpes simplex virus 2 (HSV2). A vaccine that could bring an end to this global pandemic is needed desperately, yet no candidate vaccine has ever performed well in clinical trials. Now scientists in […]
(PRNewswire) According to a recent press release, Rational Vaccines, a biotechnology company at the forefront of herpes research, announced today groundbreaking results from a Phase I Clinical Trial of their potentially revolutionary TheravaxHSV-2 vaccine.
(PR Newswire) Rational Vaccines (RVx), a new biotechnology startup, aims to stop the spread of herpes and improve treatment options for millions of people who live with recurrent herpetic disease. Based on 20 years of pre-clinical studies, RVx has developed a new class of rationally-engineered live vaccines that may safely and effectively prevent the spread […]